Blood Stream Infections by Candida glabrata and Candida krusei: A Single-Center Experience
3
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: The increasing incidence of Candida glabrata and Candida krusei infections is a significant problem because they are generally more resistant to fluconazole. We compared the risk factors associated with C. glabrata and C. krusei fungemia with Candida albicans fungemia and examined the clinical manifestations and prognostic factors associated with candidemia. Methods: We retrospectively reviewed demographic data, risk factors, clinical manifestations, and outcomes associated with C. glabrata and C. krusei fungemia at a tertiary-care teaching hospital during a 10-years period from 1997 to 2006. Results: During the study period, there were 497 fungemia episodes. C. glabrata fungemia accounted for 23 episodes and C. krusei fungemia accounted for 8. Complete medical records were available for 27 of these episodes and form the basis of this study. Compared to 54 episodes of C. albicans fungemia, renal insufficiency and prior fluconazole prophylaxis were associated with development of C. glabrata or C. krusei fungemia. The overall mortality was 67%. The fungemia-related mortality of C. glabrata and C. krusei was higher than that of C. albicans (52 vs. 26%, p=0.021). Empirical antifungal therapy did not decrease the crude mortality. Multiple logistic regression analysis showed that high APACHE Ⅱ scores, catheter maintenance, and shock were independently associated with an increased risk of death. Conclusions: Renal insufficiency and prior fluconazole prophylaxis were associated with the development of C. glabrata or C. krusei fungemia. Fungemia-related mortality of C. glabrata or C. krusei was higher than that of C. albicans. Outcomes appeared to be related to catheter removal, APACHE Ⅱ scores, and shock.
Abstract
Background/Aims: The increasing incidence of Candida glabrata and Candida krusei infections is a significant problem because they are generally more resistant to fluconazole. We compared the risk factors associated with C. glabrata and C. krusei fungemia with Candida albicans fungemia and examined the clinical manifestations and prognostic factors associated with candidemia. Methods: We retrospectively reviewed demographic data, risk factors, clinical manifestations, and outcomes associated with C. glabrata and C. krusei fungemia at a tertiary-care teaching hospital during a 10-years period from 1997 to 2006. Results: During the study period, there were 497 fungemia episodes. C. glabrata fungemia accounted for 23 episodes and C. krusei fungemia accounted for 8. Complete medical records were available for 27 of these episodes and form the basis of this study. Compared to 54 episodes of C. albicans fungemia, renal insufficiency and prior fluconazole prophylaxis were associated with development of C. glabrata or C. krusei fungemia. The overall mortality was 67%. The fungemia-related mortality of C. glabrata and C. krusei was higher than that of C. albicans (52 vs. 26%, p=0.021). Empirical antifungal therapy did not decrease the crude mortality. Multiple logistic regression analysis showed that high APACHE Ⅱ scores, catheter maintenance, and shock were independently associated with an increased risk of death. Conclusions: Renal insufficiency and prior fluconazole prophylaxis were associated with the development of C. glabrata or C. krusei fungemia. Fungemia-related mortality of C. glabrata or C. krusei was higher than that of C. albicans. Outcomes appeared to be related to catheter removal, APACHE Ⅱ scores, and shock.
참고문헌 (27)
- Wisplinghoff H, "Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study", Clin Infect Dis, 39, pp.309~317 (2004)
- Abi-Said D, "The epidemiology of hematogenous candidiasis caused by different Candida species", Clin Infect Dis, 24, pp.1122~1128 (1997)
- Orozco AS, "Mechanism of fluconazole resistance in Candida krusei", Antimicrob Agents Chemother, 42, pp.2645~2649 (1998)
- Parkinson T, "Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata", Antimicrob Agents Chemother, 39, pp.1696~1699 (1995)
- Nguyen MH, "The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance", Am J Med, 100, pp.617~623 (1996)
- Voss A, "Occurrence of yeast bloodstream infections between 1987 and 1995 in five Dutch university hospitals", Eur J Clin Microbiol Infect Dis, 15, pp.909~912 (1996)
- Pfaller MA, "International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program", J Clin Microbiol, 36, pp.1886~1889 (1998)
- Klevay MJ, "Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection", Diagn Microbiol Infect Dis, 60, pp.273~277 (2008)
- Blot S, "Outcome in critically ill patients with candidal fungaemia: Candida albicans vs. Candida glabrata", J Hosp Infect, 47, pp.308~313 (2001)
- Bassetti M, "Incidence, risk factors, and predictors of outcome of candidemia: survey in 2 Italian university hospitals", Diagn Microbiol Infect Dis, 58, pp.325~331 (2007)
- Abbas J, "Candida krusei fungemia: an escalating serious infection in immunocompromised patients", Arch Intern Med, 160, pp.2659~2664 (2000)
- Marr KA, "Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole", J Infect Dis, 181, pp.309~316 (2000)
- Lin MY, "Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study", Antimicrob Agents Chemother, 49, pp.4555~4560 (2005)
- Diekema DJ, "Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study", J Clin Microbiol, 40, pp.1298~1302 (2002)
- Malani A, "Candida glabrata fungemia: experience in a tertiary care center", Clin Infect Dis, 41, pp.975~981 (2005)
- Bodey GP, "The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer", Am J Med, 112, pp.380~385 (2002)
- White MH, "The contribution of fluconazole to the changing epidemiology of invasive candidal infections", Clin Infect Dis, 24, pp.1129~1130 (1997)
- Safdar A, "Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome", Bone Marrow Transplant, 28, pp.873~878 (2001)
- Pappas PG, "A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients", Clin Infect Dis, 37, pp.634~643 (2003)
- Viudes A, "Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death", Eur J Clin Microbiol Infect Dis, 21, pp.767~774 (2002)
- Morrell M, "Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality", Antimicrob Agents Chemother, 49, pp.3640~3645 (2005)
- Michalopoulos AS, "Determinants of candidemia and candidemia-related death in cardiothoracic ICU patients", Chest, 124, pp.2244~2255 (2003)
- Chen S, "Active surveillance for candidemia, Australia", Emerg Infect Dis, 12, pp.1508~1516 (2006)
- Antoniadou A, "Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy", Medicine, 82, pp.309~321 (2003)
- Garey KW, "Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multiinstitutional study", Clin Infect Dis, 43, pp.25~31 (2006)
- Goodrich JM, "Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation", J Infect Dis, 164, pp.731~740 (1991)
- Anaissie EJ, "Predictors of adverse outcome in cancer patients with candidemia", Am J Med, 104, pp.238~245 (1998)